Aprea Therapeutics opened higher at $0.45, compared with its previous close of $0.44. In the last trading session, the stock traded between $0.44 and $0.45. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aprea Therapeutics is now worth
$ 0.45
Resulting in a loss of
$ 99.55 (99.55%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.00 (-0.79%)
Day High
$0.45
Day Low
$0.44
Day Open
$0.45
Prev Close
$0.44
Volume
33,548
1W Return
-13.36%
1M Return
-25.76%
3M Return
-34.18%
6M Return
-52.60%
1Y Return
-66.59%
Fundamentals
Market Cap ($ Mn)
6
PE Ratio
-
PB Ratio
0.27
PEG Ratio
-
ROE
-87.95%
ROCE
-86.69%
EPS (TTM)
$-0.27
Investment Returns
1 Week
-13.36%
1 Month
-25.76%
3 Months
-34.18%
6 Months
-52.60%
9 Months
-28.11%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
Updates
4Nov
Aprea Therapeutics Q3 Results: Loss widens 81% YoY, misses estimate
Aprea Therapeutics posted a Q3 loss of $0.09 per share. Result missed the analyst consensus estimate of $0.07 by 28.57%. Losses increased 80.85% year-over-year from $0.47 per share.
8 days ago
16Oct
Aprea Therapeutics to host virtual panel on WEE1 inhibition ahead of ESMO
Aprea Therapeutics hosts a virtual panel on WEE1 inhibition on October 20, 2026. Panel precedes the European Society for Medical Oncology (ESMO) Congress 2026. Lead program APR-1051 is an oral WEE1 kinase inhibitor in Phase 1 trials. Discussion covers biology, selectivity challenges, and market perspectives.
27 days ago
28Aug
Aprea Therapeutics updates patent portfolio for oncology programs
Aprea Therapeutics updated its patent portfolio on August 28, 2026. WEE1 inhibitor patents could expire in 2047 if granted. ATR inhibitor holds 22 granted non-U.S. patents. APR-1051 is in Phase 1 trial for solid tumors.
